• Publications
  • Influence
Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
[F-18]FLT (3'-deoxy-3'-fluorothymidine) is developed and tested; it is resistant to degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and produces high-contrast images of normal marrow and tumors in canine and human subjects. Expand
Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.
Results suggest that FLT images reflect TK(1) activity and the percentage of cells in S phase, and suggest that inhibition of cell cycle progression prevents FLT uptake and increased TK-1 activity. Expand
Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer
Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer. Expand
Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.
Although there is a general tendency toward improved oxygenation in human tumors during fractionated radiotherapy, these changes are unpredictable and may be insufficient in extent and timing to overcome the negative effects of existing pretreatment hypoxia. Expand
Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
These analyses depict model behavior and provide expected values for the accuracy of parameter estimates from FLT imaging in human patients, and determine the fidelity of K(FLT) (FLT flux) as a proxy for K(TDR) (thymidine flux), the gold standard for imaging cellular proliferation. Expand
Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
Modeling analysis of 18F-FLT PET data yielded robust estimates of K1 and K(FLT) for enhancing tumors with sufficiently high K1 values and provides a clearer understanding of the relationship between transport and retention of 18C-thymidine in gliomas. Expand
Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.
The first experiences with PETT imaging of [F-18]FMISO uptake in human malignancies are presented, and the development of this technique as a tool for the non-invasive assessment of tumor hypoxia is described. Expand
Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT)
Abstract[18F]FLT (3′-deoxy-3′-[18F]fluorothymidine) turned out to be a tracer particularly suitable for PET imaging of tumor proliferation because of lacking degradation in vivo. To facilitateExpand
FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine.
FLT-PET should be considered a powerful addition to FDG-PET, providing additional diagnostic specificity and important biological information that could be useful in predicting prognosis, planning treatment, and monitoring response. Expand
In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67
FLT PET may be used to noninvasively assess proliferation rates of lung masses in vivo and play a significant role in the evaluation of indeterminate pulmonary lesions, in the prognostic assessment of resectable NSCLC, and possibly in the Evaluation of NSCLCs response to chemotherapy. Expand